Use of Intranasal Oxytocin to Treat Adult Autism Spectrum Disorder: A Randomized Double Blind Controlled Trial
IntroductionAutism Spectrum Disorder (ASD) is characterized by impairments in social interaction and restricted interests. It has been reported that oxytocin may improve processing of social cues and emotions in adults with ASD.ObjectivesThe aim of this study was to evaluate the therapeutic effects...
Gespeichert in:
Veröffentlicht in: | European psychiatry 2024-08, Vol.67 (S1), p.S48-S49 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | IntroductionAutism Spectrum Disorder (ASD) is characterized by impairments in social interaction and restricted interests. It has been reported that oxytocin may improve processing of social cues and emotions in adults with ASD.ObjectivesThe aim of this study was to evaluate the therapeutic effects and safety of intranasal oxytocin in this population.MethodsThirty-nine patients with ASD were randomly assigned to two groups: one group received intranasal oxytocin and the other group received a placebo, with 24 units administered every 12 hours for 8 weeks. The patients were evaluated using the Autism Quotient (AQ), Ritvo Autism Asperger Diagnostic Scale – Revised (RAADS-R), Social Responsiveness Scale (SRS), Clinical Global Impression (CGI), and World Health Organization Quality of Life-BREF (WHOQL-BREF) questionnaires at weeks 0, 4, and 8.ResultsThe intervention group showed clinical improvements in RAADS-R (P=0.010), social communication subscale of SRS (P=0.002), CGI (P=0.000), physical (P=0.004), psychological (P=0.006), and social relationships (P=0.046) domains of WHOQL-BREF. Improvements reached their maximum at week 4 and were maintained until week 8 (Table 1).Table 1.Effect of group, time time-group interaction and the effect sizeTimeGroupTime-Group InteractionFP-ValueEffect Size (Partial Eta Squared)FP-ValueEffect Size(Partial Eta Squared)FP-ValueEffect Size(Partial Eta Squared)AQ19.440.0000.3440.3910.5360.012.630.0790.066RAADS-R12.680.0000.2550.9440.3380.0257.2500.0010.164SRS23.630.0000.3900.0500.8230.0017.820.0010.175WHOQL-BREF -Physical Health6.340.0030.1460.1150.7370.0035.70.0050.134WHOQL-BREF -Psychological Health8.310.0010.1830.0480.8280.0016.140.0030.142WHOQL-BREF -Social Relationships7.720.0010.1731.0520.3120.0283.640.0310.090WHOQL-BREF -Environmental Health4.870.0100.1160.1620.6900.0042.690.0740.068CGI22.080.0000.3742.280.1390.0589.420.0040.203AQ : Autism Spectrum Quotient, SRS : Social Responsiveness Scale, SCI : Social Communication Interaction, RRB : Restricted interest and repetitive behavior, WHOQL-BREF : World Health Organization Quality of life-BREF, CGI : Clinical Global ImpressionConclusionsThe findings of this study suggest that nasal oxytocin therapy can significantly improve social skills and quality of life in individuals with ASD. Further research is needed to determine the timing and scope of oxytocin’s effects across the lifespan.Disclosure of InterestNone Declared |
---|---|
ISSN: | 0924-9338 1778-3585 |
DOI: | 10.1192/j.eurpsy.2024.151 |